181 related articles for article (PubMed ID: 29173764)
1. Clinical outcomes of black vs. non-black patients with locally advanced non-small cell lung cancer.
Vyfhuis MAL; Bhooshan N; Molitoris J; Bentzen SM; Feliciano J; Edelman M; Burrows WM; Nichols EM; Suntharalingam M; Donahue J; Nagib M; Carr SR; Friedberg J; Badiyan S; Simone CB; Feigenberg SJ; Mohindra P
Lung Cancer; 2017 Dec; 114():44-49. PubMed ID: 29173764
[TBL] [Abstract][Full Text] [Related]
2. Implications of Pathologic Complete Response Beyond Mediastinal Nodal Clearance With High-Dose Neoadjuvant Chemoradiation Therapy in Locally Advanced, Non-Small Cell Lung Cancer.
Vyfhuis MAL; Burrows WM; Bhooshan N; Suntharalingam M; Donahue JM; Feliciano J; Badiyan S; Nichols EM; Edelman MJ; Carr SR; Friedberg J; Henry G; Stewart S; Sachdeva A; Pickering EM; Simone CB; Feigenberg SJ; Mohindra P
Int J Radiat Oncol Biol Phys; 2018 Jun; 101(2):445-452. PubMed ID: 29559292
[TBL] [Abstract][Full Text] [Related]
3. Insurance Status is an Independent Predictor of Overall Survival in Patients With Stage III Non-small-cell Lung Cancer Treated With Curative Intent.
Rice SR; Vyfhuis MAL; Scilla KA; Burrows WM; Bhooshan N; Suntharalingam M; Edelman MJ; Feliciano J; Badiyan SN; Simone CB; Bentzen SM; Feigenberg SJ; Mohindra P
Clin Lung Cancer; 2020 May; 21(3):e130-e141. PubMed ID: 31708388
[TBL] [Abstract][Full Text] [Related]
4. Patterns of Care and Survival in Stage III NSCLC Among Black and Latino Patients Compared With White Patients.
Vyfhuis MAL; Bentzen SM; Molitoris JK; Diwanji T; Badiyan S; Grover S; Adebamowo CA; Simone CB; Mohindra P
Clin Lung Cancer; 2019 Jul; 20(4):248-257.e4. PubMed ID: 30910573
[TBL] [Abstract][Full Text] [Related]
5. The Effect of Body Mass Index and Residence in Food Priority Areas on Patterns-of-Care and Cancer Outcomes in Patients With Stage III Non-Small Cell Lung Cancer.
Savla B; Hamza MA; Yacubovich D; Cobbs S; Petrovska L; Scilla KA; Burrows W; Mehra R; Miller RC; Rolfo C; Bentzen SM; Mohindra P; Vyfhuis MAL
Int J Radiat Oncol Biol Phys; 2023 May; 116(1):50-59. PubMed ID: 36720317
[TBL] [Abstract][Full Text] [Related]
6. Health care disparities among octogenarians and nonagenarians with stage III lung cancer.
Cassidy RJ; Zhang X; Switchenko JM; Patel PR; Shelton JW; Tian S; Nanda RH; Steuer CE; Pillai RN; Owonikoko TK; Ramalingam SS; Fernandez FG; Force SD; Gillespie TW; Curran WJ; Higgins KA
Cancer; 2018 Feb; 124(4):775-784. PubMed ID: 29315497
[TBL] [Abstract][Full Text] [Related]
7. Real-World Treatment of Stage III NSCLC: The Role of Trimodality Treatment in the Era of Immunotherapy.
Moore S; Leung B; Wu J; Ho C
J Thorac Oncol; 2019 Aug; 14(8):1430-1439. PubMed ID: 31002953
[TBL] [Abstract][Full Text] [Related]
8. Oncological outcomes from trimodality therapy receiving definitive doses of neoadjuvant chemoradiation (≥60 Gy) and factors influencing consideration for surgery in stage III non-small cell lung cancer.
Vyfhuis MAL; Bhooshan N; Burrows WM; Turner M; Suntharalingam M; Donahue J; Nichols EM; Feliciano J; Bentzen SM; Badiyan S; Carr SR; Friedberg J; Simone CB; Edelman MJ; Feigenberg SJ; Mohindra P
Adv Radiat Oncol; 2017; 2(3):259-269. PubMed ID: 29114590
[TBL] [Abstract][Full Text] [Related]
9. Survival results and prognostic factors in T4 N0-3 non-small cell lung cancer patients according to the AJCC 7th edition staging system.
Arslan D; Bozcuk H; Gunduz S; Tural D; Tattli AM; Uysal M; Goksu SS; Bassorgun Cİ; Koral L; Coskun HS; Ozdogan M; Savas B
Asian Pac J Cancer Prev; 2014; 15(6):2465-72. PubMed ID: 24761848
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant chemoradiation and surgery improves survival outcomes compared with definitive chemoradiation in the treatment of stage IIIA N2 non-small-cell lung cancer.
Darling GE; Li F; Patsios D; Massey C; Wallis AG; Coate L; Keshavjee S; Pierre A; De Perrot M; Yasufuku K; Cypel M; Waddell T
Eur J Cardiothorac Surg; 2015 Nov; 48(5):684-90; discussion 690. PubMed ID: 25567960
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent.
Zhu J; Li R; Tiselius E; Roudi R; Teghararian O; Suo C; Song H
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011300. PubMed ID: 29247502
[TBL] [Abstract][Full Text] [Related]
12. Trimodality therapy for stage IIIA non-small cell lung cancer: benchmarking multi-disciplinary team decision-making and function.
Dickhoff C; Hartemink KJ; van de Ven PM; van Reij EJ; Senan S; Paul MA; Smit EF; Dahele M
Lung Cancer; 2014 Aug; 85(2):218-23. PubMed ID: 24976333
[TBL] [Abstract][Full Text] [Related]
13. Understanding clinical practice and survival outcomes in patients with unresectable stage III non-small-cell lung cancer in a single centre in Quebec.
Agulnik J; Kasymjanova G; Pepe C; Hurry M; Walton RN; Sakr L; Cohen V; Lecavalier M; Small D
Curr Oncol; 2020 Oct; 27(5):e459-e466. PubMed ID: 33173385
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of weight gain during definitive chemoradiotherapy for locally advanced non-small-cell lung cancer.
Sher DJ; Gielda BT; Liptay MJ; Warren WH; Batus M; Fidler MJ; Garg S; Bonomi P
Clin Lung Cancer; 2013 Jul; 14(4):370-5. PubMed ID: 23260389
[TBL] [Abstract][Full Text] [Related]
15. Association of Immune-Related Adverse Events and Efficacy Outcomes With Consolidation Pembrolizumab After Chemoradiation in Patients With Inoperable Stage III Non-Small-Cell Lung Cancer.
Shukla NA; Althouse S; Meyer Z; Hanna N; Durm G
Clin Lung Cancer; 2021 Jul; 22(4):274-281. PubMed ID: 33610454
[TBL] [Abstract][Full Text] [Related]
16. [Value of surgery for stage IIIa non-small cell lung cancer].
Liu H; Wang M; Hu K; Xu Y; Ma M; Zhong W; Zhao J; Li L; Wang H
Zhongguo Fei Ai Za Zhi; 2013 Dec; 16(12):639-45. PubMed ID: 24345488
[TBL] [Abstract][Full Text] [Related]
17. Neo-adjuvant Chemo-Radiation to 60 Gray Followed by Surgery for Locally Advanced Non-Small Cell Lung Cancer Patients: Evaluation of Trimodality Strategy.
Appel S; Goldstein J; Perelman M; Rabin T; Urban D; Onn A; Shulimzon TR; Weiss I; Lieberman S; Marom EM; Golan N; Simansky D; Ben-Nun A; Lawrence YR; Bar J; Symon Z
Isr Med Assoc J; 2017 Oct; 19(10):614-619. PubMed ID: 29103238
[TBL] [Abstract][Full Text] [Related]
18. Guideline-concordant Care Improves Overall Survival for Locally Advanced Non-Small-cell Lung Carcinoma Patients: A National Cancer Database Analysis.
Ahmed HZ; Liu Y; O'Connell K; Ahmed MZ; Cassidy RJ; Gillespie TW; Patel P; Pillai RN; Behera M; Steuer CE; Owonikoko TK; Ramalingam SS; Curran WJ; Higgins KA
Clin Lung Cancer; 2017 Nov; 18(6):706-718. PubMed ID: 28601387
[TBL] [Abstract][Full Text] [Related]
19. Radical radiotherapy or chemoradiotherapy for inoperable, locally advanced, non-small cell lung cancer: Analysis of patient profile, treatment approaches, and outcomes for 213 patients at a tertiary cancer center.
Shrimali RK; Nallathambi C; Saha A; Das A; Prasath S; Mahata A; Arun B; Mallick I; Achari R; Dabkara D; Thambudorai R; Chatterjee S
Indian J Cancer; 2018; 55(2):125-133. PubMed ID: 30604722
[TBL] [Abstract][Full Text] [Related]
20. Factors associated with treatment receipt and overall survival for patients with locally advanced large cell neuroendocrine carcinoma of the lung: A National Cancer Database analysis.
Limonnik V; Abel S; Finley GG; Long GS; Wegner RE
Lung Cancer; 2020 Dec; 150():107-113. PubMed ID: 33126090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
